2 No-Brainer Dividend Stocks to Buy in 2026

Dividend stocks are not each the same. Some volition readily alteration oregon suspend their payouts astatine the archetypal motion of trouble, portion others volition proceed expanding them adjacent during marketplace downturns oregon economical recessions.

Dividend investors similar those that are successful the second category. Let's see 2 stocks on those lines that are worthy buying: Johnson & Johnson (NYSE: JNJ) and Zoetis (NYSE: ZTS). These 2 healthcare companies are fantabulous picks for income-oriented investors.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

Johnson & Johnson has galore qualities that semipermanent income seekers seek. The company's business, albeit not peculiarly exciting, is accordant and resilient. Johnson & Johnson is simply a starring pharmaceutical institution with a immense portfolio of approved medicines, arsenic good arsenic a aesculapian instrumentality person operating crossed respective therapeutic areas.

Revenue and net typically turn astatine a decent clip. That's the lawsuit adjacent erstwhile it encounters problems specified arsenic patent cliffs and government-led cause terms negotiations -- issues it is presently dealing with, but it expects its yearly reported income to turn this twelvemonth and apical $100 cardinal for the archetypal time. Johnson & Johnson besides has a rock-solid equilibrium sheet, evidenced by its higher recognition standing than the U.S. government's.

Further, Johnson & Johnson is an innovative company. It routinely launches caller products, some successful its biopharma and medtech divisions, that assistance it antagonistic stiff competition, whether biosimilar oregon otherwise.

Johnson & Johnson is present awaiting support for its robotic-assisted country system, the Ottava, that could beryllium an important maturation operator implicit the agelong run. And the company's pharmaceutical pipeline features respective twelve ongoing objective trials that volition assistance it replenish its portfolio and gain important statement expansions.That's however the institution has performed good implicit the agelong run.

Finally, Johnson & Johnson is simply a Dividend King, a institution with astatine slightest 50 consecutive yearly dividend hikes. That's what helps marque it an outstanding income banal that dividend investors shouldn't deliberation doubly about.

Zoetis is simply a starring carnal wellness company. It deed immoderate headwinds past year, arsenic 2 of its maturation drivers, Librela and Solensia, which dainty osteoarthritis (OA) symptom successful dogs and cats, respectively, raised information concerns; this contented peculiarly affected Librela.